TITILOPE OMISAKIN: Open Payments
NPI 1407536345 · PLYMOUTH, MN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$146 in 9 payments from 8 companies in 2025. Trend: 2023 $136 · 2024 $233 · 2025 $146
Food & beverage: $146
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| ABBVIE INC. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Sage Therapeutics, LLC | 1 | $13 |
Products named: FANAPT, Qelbree, Jornay PM, VRAYLAR, REXULTI, TRINTELLIX, LOREEV XR, ZURZUVAE.
Industry payments across MN — which companies pay providers there.
